Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Can Low-Dose CBD Cannabis Calm Dementia Patients Without Sedation? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As research into cannabis-based treatments expands, many families wonder if low-dose CBD could help calm agitation in dementia without causing drowsiness or confusion. Current evidence suggests there may be some potential, but the data remains early and mixed. 

Can medical cannabis be accessed legally for women’s health?

What The Research Shows 

Low dose cannabidiol (CBD) is being studied for its potential calming effects on behavioural symptoms in dementia. A 2022 trial published in Frontiers in Medicine found that CBD-rich cannabis oil reduced agitation and improved sleep compared with placebo. Most participants tolerated the treatment well, but mild side effects such as fatigue and appetite changes were reported. 

Earlier observational work and systematic reviews, including a 2021 meta-analysis in PMC, suggest that low to moderate doses of CBD (under 20 mg twice daily) may reduce restlessness and aggression in some patients, although results vary widely.  

What The Guidelines Say 

According to NICE guidance (NG144, updated 2025) and the NHS, cannabis-based medicinal products, including CBD, are not recommended for managing agitation or behavioural changes in dementia outside of research trials. The World Health Organization (WHO) has also stated that while CBD appears generally safe and non-intoxicating, its use for dementia-related symptoms is still unproven. 

Safety And Sedation 

Unlike THC, CBD is not intoxicating and does not typically cause the “high” associated with cannabis. However, sedation can still occur, especially at higher doses or in older adults taking other medications that affect the central nervous system. 

The Alzheimer’s Society notes that while CBD may help some people feel calmer, there is no consistent evidence that it reduces agitation without drowsiness. Clinicians remain cautious, as frail patients are particularly vulnerable to balance problems and falls. 

Expert Consensus 

The Royal College of Psychiatrists and Mayo Clinic advise that any cannabinoid use for dementia should occur only in closely monitored clinical settings.  

Clinical Bottom Line 

  • Low-dose CBD may reduce agitation in dementia, but evidence remains limited. 
  • Sedation can still occur, particularly in frail or medicated patients. 
  • NICE and NHS do not support CBD use for dementia symptoms outside trials. 
  • CBD appears safer and less psychoactive than THC but should be used only under research protocols. 
  • More large-scale, placebo-controlled studies are needed to confirm benefits. 

About AlleviMed  

If you are exploring whether medical cannabis could be suitable for a loved one, services such as AlleviMed (launching soon) can offer eligibility consultations. These sessions help patients and families understand if cannabis-based treatments could be clinically and legally appropriate under current UK regulations. 

Takeaway 

Low-dose CBD may show some promise for calming agitation in dementia, but evidence is still limited and inconsistent. It appears less sedating than THC, yet not entirely free from drowsiness or drug interactions. The NHS and NICE both recommend restricting its use to formal research studies until clearer safety and effectiveness of data are available. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories